Katharine M Esselen1, Angel M Cronin2, Kristin Bixel3, Michael A Bookman4, Robert A Burger5, David E Cohn3, Mihaela Cristea6, Jennifer J Griggs7, Charles F Levenback8, Gina Mantia-Smaldone9, Larissa A Meyer8, Ursula A Matulonis2, Joyce C Niland6, Charlotte Sun8, David M O'Malley3, Alexi A Wright2. 1. Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts. 2. Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 3. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Comprehensive Cancer Center, Columbus. 4. US Oncology Research and Arizona Oncology, Tucson. 5. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia. 6. Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California. 7. Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor8Division of Hematology and Oncology, Department of Health Management and Policy, University of Michigan Comprehensive Cancer Center, Ann Arbor. 8. Division of Surgery, Department of Gynecologic and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston. 9. Division of Gynecologic Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Abstract
IMPORTANCE: A 2009 randomized clinical trial demonstrated that using cancer antigen 125 (CA-125) tests for routine surveillance in ovarian cancer increases the use of chemotherapy and decreases patients' quality of life without improving survival, compared with clinical observation. The Society of Gynecologic Oncology guidelines categorize CA-125 testing as optional and discourage the use of radiographic imaging for routine surveillance. To date, few studies have examined the use of CA-125 tests in clinical practice. OBJECTIVES: To examine the use of CA-125 tests and computed tomographic (CT) scans in clinical practice before and after the 2009 randomized clinical trial and to estimate the economic effect of surveillance testing. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort of 1241 women with ovarian cancer in clinical remission after completion of primary cytoreductive surgery and chemotherapy at 6 National Cancer Institute-designated cancer centers between January 1, 2004, and December 31, 2011, was followed up through December 31, 2012, to study the use of CA-125 tests and CT scans before and after 2009. Data analysis was conducted from April 9, 2014, to March 28, 2016. MAIN OUTCOMES AND MEASURES: The use of CA-125 tests and CT scans before and after 2009. Secondary outcomes included the time from CA-125 markers doubling to retreatment among women who experienced a rise in CA-125 markers before and after 2009, and the costs associated with surveillance testing using 2015 Medicare reimbursement rates. RESULTS: Among 1241 women (mean [SD] age 59 [12] years; 1112 white [89.6%]), the use of CA-125 testing and CT scans was similar during the study period. During 12 months of surveillance, the cumulative incidence of patients undergoing 3 or more CA-125 tests was 86% in 2004-2009 vs 91% in 2010-2012 (P = .95), and the cumulative incidence of patients undergoing more than 1 CT scan was 81% in 2004-2009 vs 78% in 2010-2012 (P = .50). Among women whose CA-125 markers doubled (n = 511), there was no significant difference in the time to retreatment with chemotherapy before and after 2009 (median, 2.8 vs 3.5 months; P = .40). During a 12-month period, there was a mean of 4.6 CA-125 tests and 1.7 CT scans performed per patient, resulting in a US population surveillance cost estimate of $1 999 029 per year for CA-125 tests alone and $16 194 647 per year with CT scans added. CONCLUSIONS AND RELEVANCE: CA-125 tests and CT scans are still routinely used for surveillance testing in patients with ovarian cancer, although their benefit has not been proven and their use may have significant implications for patients' quality of life as well as costs.
IMPORTANCE: A 2009 randomized clinical trial demonstrated that using cancer antigen 125 (CA-125) tests for routine surveillance in ovarian cancer increases the use of chemotherapy and decreases patients' quality of life without improving survival, compared with clinical observation. The Society of Gynecologic Oncology guidelines categorize CA-125 testing as optional and discourage the use of radiographic imaging for routine surveillance. To date, few studies have examined the use of CA-125 tests in clinical practice. OBJECTIVES: To examine the use of CA-125 tests and computed tomographic (CT) scans in clinical practice before and after the 2009 randomized clinical trial and to estimate the economic effect of surveillance testing. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort of 1241 women with ovarian cancer in clinical remission after completion of primary cytoreductive surgery and chemotherapy at 6 National Cancer Institute-designated cancer centers between January 1, 2004, and December 31, 2011, was followed up through December 31, 2012, to study the use of CA-125 tests and CT scans before and after 2009. Data analysis was conducted from April 9, 2014, to March 28, 2016. MAIN OUTCOMES AND MEASURES: The use of CA-125 tests and CT scans before and after 2009. Secondary outcomes included the time from CA-125 markers doubling to retreatment among women who experienced a rise in CA-125 markers before and after 2009, and the costs associated with surveillance testing using 2015 Medicare reimbursement rates. RESULTS: Among 1241 women (mean [SD] age 59 [12] years; 1112 white [89.6%]), the use of CA-125 testing and CT scans was similar during the study period. During 12 months of surveillance, the cumulative incidence of patients undergoing 3 or more CA-125 tests was 86% in 2004-2009 vs 91% in 2010-2012 (P = .95), and the cumulative incidence of patients undergoing more than 1 CT scan was 81% in 2004-2009 vs 78% in 2010-2012 (P = .50). Among women whose CA-125 markers doubled (n = 511), there was no significant difference in the time to retreatment with chemotherapy before and after 2009 (median, 2.8 vs 3.5 months; P = .40). During a 12-month period, there was a mean of 4.6 CA-125 tests and 1.7 CT scans performed per patient, resulting in a US population surveillance cost estimate of $1 999 029 per year for CA-125 tests alone and $16 194 647 per year with CT scans added. CONCLUSIONS AND RELEVANCE: CA-125 tests and CT scans are still routinely used for surveillance testing in patients with ovarian cancer, although their benefit has not been proven and their use may have significant implications for patients' quality of life as well as costs.
Authors: Garo Z Harmandayan; Feng Gao; David G Mutch; Katherine S Virgo; Randall K Gibb; Frank E Johnson Journal: Gynecol Oncol Date: 2011-02 Impact factor: 5.482
Authors: Ritu Salani; Floor J Backes; Michael Fung Kee Fung; Christine H Holschneider; Lynn P Parker; Robert E Bristow; Barbara A Goff Journal: Am J Obstet Gynecol Date: 2011-06 Impact factor: 8.661
Authors: Pamela R Soulos; James B Yu; Kenneth B Roberts; Ann C Raldow; Jeph Herrin; Jessica B Long; Cary P Gross Journal: J Clin Oncol Date: 2012-03-05 Impact factor: 44.544
Authors: Patricia A Parker; Andrzej Kudelka; Karen Basen-Engquist; John Kavanagh; Janet de Moor; Lorenzo Cohen Journal: Gynecol Oncol Date: 2005-10-20 Impact factor: 5.482
Authors: Gordon J S Rustin; Maria E L van der Burg; Clare L Griffin; David Guthrie; Alan Lamont; Gordon C Jayson; Gunnar Kristensen; César Mediola; Corneel Coens; Wendi Qian; Mahesh K B Parmar; Ann Marie Swart Journal: Lancet Date: 2010-10-02 Impact factor: 79.321
Authors: Stephen Shuford; Christine Wilhelm; Melissa Rayner; Ashley Elrod; Melissa Millard; Christina Mattingly; Alina Lotstein; Ashley M Smith; Qi Jin Guo; Lauren O'Donnell; Jeffrey Elder; Larry Puls; S John Weroha; Xiaonan Hou; Valentina Zanfagnin; Alpa Nick; Michael P Stany; G Larry Maxwell; Thomas Conrads; Anil K Sood; David Orr; Lillia M Holmes; Matthew Gevaert; Howland E Crosswell; Teresa M DesRochers Journal: Sci Rep Date: 2019-08-01 Impact factor: 4.379